Author: Editor

SWOG S1801 Trial: Pembro After or Before Surgery? [2022] It is not yet known which type of immunotherapy, adjuvant or neoadjuvant, is more effective in the treatment of high-risk melanoma; this question has not been answered. The findings of this trial provide additional evidence regarding the conditions under which one approach might be more beneficial than the other.    It has been demonstrated that neoadjuvant immunotherapy can induce spectacular complete pathologic responses, which, up until this point, have been associated with a sustainable response. Patients with clinically detectable high-risk melanoma (that have received prior radiation therapy) are more likely to…

M14TIL Trial: TIL Compared to Std. Ipilimumab [2022] This is the first experiment to use tumor-infiltrating lymphocytes (TIL) in metastatic cancer. The results have shown an advantage in progression-free survival (PFS). The findings of this clinical trial may serve as a springboard for additional research into the use of TIL in other forms of cancer, with the potential to demonstrate benefit in a wide variety of other solid tumors and to increase the number of therapy options accessible to patients (treated with TIL). While immunotherapy can provide spectacular long-term responses, a significant portion of patients treated will have no response…

Shahid Gilani, MD speaks about Cancer‐Associated Thrombosis (CAT), Emerging Concepts and Paradigm shift, in Grand Round at University Hospital of North Midlands, United Kingdom. Dedicated Cancer Associated Service @sngilani

PRO in Pts With Rare Cancers: Pembrolizumab [2022]   Patient reported Outcome (PRO) in patients with rare cancers (rare diseases) treated with Pembrolizumab. Pembrolizumab’s acceptability and safety are being investigated in this study. The clinical benefit grade, as well as the objective (objectively measured) response. This phase to study, which was published in the Journal For Immunotherapy of Cancer in 2020, showed that Pembrolizumab has a favorable toxicity profile and anti-tumor activity in patients (and their clinical care) with rare cancers (rare diseases) such as squamous cell carcinoma of the skin, carcinoma of unknown primary and adrenal cortical carcinoma, paraganglioma,…

Shahid Gilani, MD from the University Hospital Of North Midlands speaks about Hypofractionated radiotherapy as a definitive treatment for Basal Cell Carcinoma: A single-institution experience. Hypofractionated RT in BCC Oncologytube BIR conference 2021 @sngilani @UHNM_NHS

Shahid Gilani, MD, Specialist doctor in Clinical Oncology from University Hospital of North Midlands, speaks about the management of Bone Health monitoring in Early Breast Cancer Patients recieving aromatase inhibitors. . ESMO Breast 2022- Bone Mineral Density screening and monitoring in EBC patients. @sngilani @UHNM_NHS

DASL-HiCaP Phase 3 Trial [2022]: Update David Wise MD   David Wise, MD Spoke with OncologyTube about the DASL-HiCaP (randomised) Phase 3 Trial The DASL (DASL-HiCaP) (randomised phase 3 clinical trial) trial. It’s one of the key trials going on right now in the non-metastatic space. And we need a lot more innovation for non-metastatic prostate cancer (or very high risk cancer). Of course, patients with this non-metastatic cancer have a far longer life expectancy and do well.   But we still certainly need to do better. And I think that Darolutamide or NUBEQA as the brand name is certainly…

Lutetium-177–PSMA-617 [2022]: Update David Wise MD   So Lutetium-PSMA-617 ((lu psma 617) prostate specific membrane antigen), we’ll call it 617 for this discussion, is already an FDA-approved agent for Progressive Metastatic Castrate Resistant Prostate Cancer (MCRPC metastatic castration resistant prostate cancer or advanced prostate cancer). The brand name is Pluvicto. The FDA approval is for men who have progressed despite 1 prior advanced hormonal therapy and at least 1 prior line of Taxane therapy.     And that agent is quite active and well tolerated. The question remains: How and in what is the best way to move this agent…

PROTECTIVE-2 Phase 3 Trial [2022] Update   Is Plinabulin a new compound? Has it been used in other disease states? Plinabulin is a small molecule. It’s a new compound. It is not yet approved. The program started as an anti-cancer program because Plinabulin has anti-cancer activity. In our phase 2 study with non-small cell lung cancer patients, we unexpectedly observed a benefit with chemo-induced (severe) neutropenia (chemotherapy induced neutropenia CIN, an adverse event). The chemo used for that was Docetaxel. Plinabulin is an anticancer agent that also has a benefit of preventing neutropenia.   And that then became a separate…

ASCO [2022] Lung Cancer In-Depth Slides: MOASC Dr. Misako Nagasaka’s (thoracic oncology) MOASC Presentation on ASCO (Annual Meeting, American Society of Clinical Oncology) 2022 ((Advanced Non) Small Cell) Lung Cancer (Trial) Thank you so much. For the opportunity today, I’m Misako Nagasaka, I’m from UC Irvine, in thoracic (clinical) oncology. Today, I will be talking about updates from ASCO 2022 (lung cancer), but in the interest of time and because of my interest, I will be focusing my talk on lung cancer for targeted therapies for (advanced) non-small cell lung cancer. Here are my disclosures. So here is…

ASCO (American Society of Clinical Oncology) [2022] Sarcomas Cancer In-Depth Slides: MOASC   Dr. Warren Chow’s MOASC Presentation on ASCO 2022 Sarcoma Cancer So I also wanna thank Jason and the organizers of MOASC (ASCO 2022 sarcoma cancer (American Society of Clinical Oncology) update) for inviting me. I’m feeling my age because I see a lot of my former fellows in academia and pharma and in practice here. These funny stories are that when I was at city hope with Joe Chao, he used to be called young Chao, and I was called old Chow.   Now I’m very old…

SOLO-1 Phase 3 [2022]: Newly Diagnosed Advanced Ovarian Cancer Research   Dr. Greg Rossi talks with OncologyTube about the SOLO-1 Phase III Trial The history of Lynparza, Olaparib, and PARP inhibitors stretches back really a couple of decades in cancer research. We had an observation a number of researchers an observation that we could target the DNA damage responses, and pathway of tumor cells as a therapeutic target, and with Olaparib, we’ve been able to do that in not just ovarian cancer, but actually in breast cancer, prostate cancer, and in pancreatic cancer.   And it really harnesses the approach…

Question and Answer Session Dr. Misako Nagasaka – ASCO [2022] Lung Cancer In-Depth Slides: MOASC Presentation https://oncologytube.com/v/41320 Misako Nagasaka, MD – About The Author, Credentials, and Affiliations At the University of California in Irvine, Dr. Nagasaka is a board-certified thoracic oncologist who specializes in the detection and treatment of lung and thyroid cancer. He also treats patients with other types of thoracic cancer. In addition to that, early-phase clinical studies, medical ethics, and survivorship care for patients are some of her clinical interests. She attended the St. Marianna University School of Medicine in Kawasaki, Japan, where she was awarded both…

Question and Answer Session Kay Yeung, MD, Ph.D. – ASCO [2022] Breast Cancer In-Depth Slides: MOASC https://oncologytube.com/v/41294 Kay Yeung, MD, Ph.D. – ASCO [2022] Breast Cancer Overview: MOASC Spotlight https://oncologytube.com/v/41282 Kay Yeung, MD, Ph.D. – About The Author, Credentials, and Affiliations Her primary area of expertise is in the clinical oncology treatment of breast cancer patients, for which she holds board certification. In order to provide patients with the most effective range of treatment options, she employs a variety of therapeutic approaches, including endocrine therapy, chemotherapy, targeted therapy, and immunotherapy. She is also a teacher at the UC San Diego School…

Question and Answer Session Justin Moyers, MD – ASCO 2022 Melanoma Overview: MOASC Spotlight https://oncologytube.com/v/41283 Justin Moyers, MD Exit Interview  https://oncologytube.com/v/41283 Zachary Hanson, DO – Anemia and Zinc Deficiency [2022]: MOASC Spotlighthttps://oncologytube.com/video/41301 Justin Moyer, MD- About The Author, Credentials, and Affiliations Medical oncologist and assistant clinical professor of medicine at the University of California, Irvine School of Medicine Justin T. Moyers is board certified in medical oncology and works at the University of California, Irvine Medical Center.   His clinical practice interests include skin cancers. Melanoma is another one of his clinical (oncology) specialties. His research interests include both the…

Question and Answer Session Joseph Chao, MD – ASCO 2022 Esophageal In-Depth Slides: MOASC Spotlight https://oncologytube.com/v/41288 Joseph Chao, MD – About The Author, Credentials, and Affiliations Joseph Chao, MD, one of Pasadena magazine’s “Top Doctors” for oncology since 2011, joined the City of Hope as a resident of oncology in 2007 and was appointed as an assistant professor with a specialty in stomach and esophageal (gastric cancer) malignancies in 2010.   Currently, he is heading clinical trial efforts to find novel therapeutics for gastroesophageal malignancies and undertaking studies to gain a better understanding of intratumoral heterogeneity in this illness.  …

Question and Answer Session   Warren Chow, MD – ASCO [2022] Sarcomas Cancer In-Depth Slides: MOASC https://oncologytube.com/v/41319 Warren Chow, MD – About The Author, Credentials, and Affiliations Dr. Warren A. Chow is an oncologist at UCI Health who is board-certified and specializes in treating patients who have melanoma and sarcoma. At the Chao Family Comprehensive Cancer Center at the University of California, Irvine, he will work as the cancer clinical sciences associate director.He attended Chicago Medical School, which is now part of Rosalind Franklin University of Medicine and Science and is located in North Chicago, Illinois. This is where he…

Question and Answer Session Arash Rezazadeh, MD, ASCO [2022] Genitourinary Cancer: MOASC Oncology Spotlight Link https://oncologytube.com/v/41291 Arash Rezazadeh, MD, ASCO 2022 Prostate Cancer Overview: MOASC Spotlight Link https://oncologytube.com/v/41285 Arash Rezazadeh, MD – About The Author, Credentials, and Affiliations Dr. Arash Rezazadeh is an Associate Clinical Professor in clinical oncology at UCI Health and a medical oncologist who focuses their practice on the treatment of urologic malignancies.

Shahid Gilani, MD, Specialist doctor in Clinical Oncology from University Hospital of North Midlands, speaks about the management of Cancer Associated Thrombosis (CAT) in a dedicated service. Cancer is the highest single risk factor for thrombosis therefore the CAT service will play an important role in improving both the outcomes and quality of life in cancer patients. A dedicated team manages cancer patients with thrombosis and in need of anticoagulation ensuring that patients get assessed, diagnosed and treated along with patient education and support they need. @sngilani @UHNM_NHS dedicated CAT Clinic

Question and Answer Session  May Cho, MD – ASCO 2022 Colon Cancer In-Depth Slides: MOASC Spotlight Link https://oncologytube.com/v/41298 May Cho, MD – ASCO 2022 Colon Cancer Overview: MOASC Spotlight Link https://oncologytube.com/v/41284 May Cho, MD – About The Author, Credentials, and Affiliations Medical oncologist at UCI Health specializing in the diagnosis and treatment of gastrointestinal cancers (gastrointestinal oncology) (colorectal cancer), Dr. May T. Cho, holds board certification in her clinical oncology field and has extensive experience in the field. She has spent a considerable amount of time working with UCI Health.

Visit http://ecancer.org/ for more. Dr Gilani (University Hospital of North Staffordshire, Stoke-on-Trent, UK) talks to ecancertv at ASCO 2014 about the effects of chemotherapy exposure in pregnant women and the regulations, or lack thereof, that protect female employees from risk. @sngilani @UHNM_NHS

Anemia and Zinc Deficiency [2022]: MOASC Spotlight   Zachary Hanson, DO MOASC Poster on Anemia Zinc Deficiency 2022 Hi, I’m Dr. Zachary Hanson from Loma Linda University Medical Center under the direction of Dr. Tari in the medical cancer center. I’ve done a research project I’d love to present to you guys. And so what we’ve done is we’ve done a retrospective review of patients with chronic anemia that was also found to have a (mild) zinc deficiency.   And so what we’ve done is we’ve looked at these patients with (severe) zinc deficiency supplemented with supplemental zinc (intake for…

Cancer and COVID-19: Thrombosis and Pro-inflammatory (cytokines)   Christopher Grant, MD, MOASC Poster on Cancer and COVID-19: Thrombosis and Pro-inflammatory Cytokines Hello, my name is Chris Grant. I’m a PGY two at UC Irvine and have an internal medicine residency. And I’d like to present my poster today on thrombosis and pro-inflammatory cytokines responses in COVID-19 with cancer at a tertiary cancer center. And so, just to begin, C is known to have many numerous coagulable factors that actually reach into that pro-inflammatory cytokine state in the OSE triad paired with that cancer also has many of those properties as…

Paraneoplastic Glomerular Nephropathy [2022]: MOASC   Xiaojie Zhang, MD Poster On Paraneoplastic Glomerular Nephropathy Hi, I’m Xiaojie Zhang, and I’m a first-year hematology-oncology fellow at the University of California San Diego. My poster today is about paraneoplastic glomerular nephropathy associated with renal cell carcinoma. This is an observational analysis of case reports published in the last four decades of patients with PGN associated with a diagnosis of renal cell carcinoma. What is PGN (paraneoplastic glomerular disease)? PGN (paraneoplastic glomerular diseases) is a rare manifestation or rare type of paraneoplastic syndromes, which is associated with a variety of solid tumors. Among…

ASCO 2022 Colon Cancer In-Depth Slides: MOASC Spotlight   May Cho, MD from UCI Health ASCO (American Society of Clinical Oncology) Annual Meeting Presentation   I have to start with this neoadjuvant and definitive immunotherapy in MSI high (locally advanced) rectal cancer (gastrointestinal cancers) (colorectal cancer), especially in localized disease with the New York time Arteris of full messages, exponential like a hundred times. And then, I will go over the role of CMMRD in the management of early-stage colon cancer (colorectal cancer, rectal cancer).   And finally, I will conclude the outcomes with optimized first-line therapy in metastatic colorectal…

This immersive practice guide offers “how to” methods and day-to-day strategies via faculty commentary and a review of data and guideline recommendations. Expert faculty address which approaches may not be working, complexities in managing this patient population, insights on how the latest evidence supports a practical recommendation and review available therapies to optimize treatment selection.   Claim credit: https://www.achlcme.org/multiple-myeloma-onctube

ASCO [2022] Breast Cancer In-Depth Slides: MOASC   Kay Yeung, MD, Ph.D. Delivers Her MOASC 2022 Breast Cancer Presentation Hello, everyone. Thank you for inviting me. And have the opportunity to really go over some breast cancer (care) updates and definitely a lot of excellent breast cancer presentations and breast cancer abstracts that was presented in 2022 ASCO (this year’s American Society of Clinical Oncology) annual meeting today this year. And I don’t have time to go over all of them, but I hope that the ones I go over will be interesting and important.   So this is my…

GI Genius vs Standard Colonoscopy: Is it Better?   Rosario Ligresti, MD, FASGE Speaks About The GI Genius Intelligent Endoscopy Module (colon cancer) For many years, colonoscopy has been considered the gold standard for colon and rectum cancer screening. And we know, based on many years worth of data suggesting how accurate colonoscopy is. But when you actually dive down somewhat more deeply between the lines, you find out that colonoscopy, as we practice it currently, may not be as accurate as intended, with potentially missed colorectal polyps. You consider some of the more recent reviews of colonoscopy and where…

Pediatric Patients with CGvHD Ibrutinib OK’d by FDA   Chronic graft versus host disease, or CGvHD, is a condition associated with immune dysregulation that can occur about 100 days post an allogeneic stem cell transplant.   It is multisystemic. It usually occurs in the skin, the liver, the GI tract, the eyes, and the lungs so that it can be all-encompassing.   It is the leading cause of non-relapse mortality, and it is generally associated with delayed immune reconstitution, as well as infections. In the pediatric world, it can have a lower incidence versus the adult world.   However, the…

ASCO [2022] Genitourinary Cancer(s): MOASC Oncology Spotlight Dr. Arash Rezazadeh’s MOASC 2022 Presentation in Genitourinary Cancers (ASCO genitourinary cancers symposium) ARASENS Trial – In Patients with Metastatic Castration Sensitive Prostate Cancer(s) (Genitourinary Cancers) ARASENS (retrospective study) was one dataset that may change the standard of care for some of the patients with prostate cancer(s). So I picked that for that reason. It’s Darolutamide versus placebo in combination with ADT docetaxel. So remember the. The standard of care in this trial was defined as ADT plus Docetaxel, and it was in patients with metastatic castrate sensitive. Prostate cancer(s) (castration resistant prostate…

ASCO 2022 Melanoma (American Society of Clinical Oncology) In-Depth Slides: MOASC Spotlight on Oncology I’ll do a brief reminder of standard treatment options and then go over the DREAMseq trial and the RELATIVITY-047 and then if there’s time, if I was adequately caffeinated or something, we’ll also go onto the KEYNOTE-716 in the PRADO clinical trials in clinical oncology that may provide new evidence (additional information). Is two better than one? Current Standard of Melanoma Treatment Is two better than one? The current standard of care was based on the CheckMate 067 trial, where there were 3 arms. 945 patients…

ASCO 2022 Esophageal In-Depth Slides: MOASC Spotlight   ASCO 2022 Esophageal Cancer Abstracts Highlights Abstracts of interest that were recently presented at ASCO (gastrointestinal cancers symposium) just this past summer, the first is the randomized phase 2 DANTE trial in clinical oncology. So I think all of us are aware of our non-metastatic patients, but locally advanced and, unfortunately in the US, because of lack of effective screening strategies, a lot of our patients, even if they’re at least diagnosed without stage 4 disease, they typically have a very bulky disease that needs perioperative chemotherapy (systemic therapy). How can this…

Cholangiocarcinoma: Ipilimumab and Nivolumab Combo   MOASC Poster Session 2022 (Cholangiocarcinoma Ipilimumab Nivolumab) Hello, my name is Dalia Kaakour (clinical oncology). I’m a PGY three internal medicine resident at the University of California Irvine. And today, I’ll be presenting a poster. It’s actually a case series on three patients (patient population) with advanced cholangiocarcinoma, to who we saw durable responses to dual age it immunotherapy with ipilimumab and nivolumab.   So what’s unique about this case series is that it provides three examples of patients that were that are still seeing responses to this combination immunotherapy (with nivolumab) after having…

Despite the advances in precision medicine for non-small cell lung cancer (NSCLC), a significant proportion of patients, particularly African American and Hispanic patients, face inequities with access to these health breakthroughs. In this activity, expert faculty focus on the latest evidence with NSCLC disparities of care and how to best overcome these barriers. The activity also reviews how to assess opportunities to increase referral of minority patients to clinical trials and how to optimize overall care coordination among minority patients with NSCLC. Claim credit: https://www.achlcme.org/reduce-health-disparities-nsclc-onctube

ASCO 2022 Prostate Cancer Overview: MOASC Spotlight   ARASENS Trial I presented at MOASC three datasets in prostate cancer from the 2022 ASCO annual meeting. The first dataset was in metastatic castration-sensitive prostate cancer, the so-called ARASENS trial phase III study.   And we presented the data with ADT plus docetaxel plus dose AEL plus minus Darolutamide. These patients continue to get the triplet or doublet until the metastatic disease progression (cancer) or has unacceptable toxicity (management).   And then, we showed that there was an overall survival benefit in a subset of patients with de novo metastatic disease or…

ASCO (American Society of Clinical Oncology) 2022 Colon Cancer Overview: MOASC Spotlight   Today I presented three clinical trials at the American Society of Clinical Oncology (ASCO) annual meeting. The first one is neoadjuvant immunotherapy in locally advanced rectal cancer (colorectal cancer). That data was presented by MSK Group and given neoadjuvant immunotherapy for six months, giving a hundred percent clinical complete response rate or response duration in locally advanced rectal cancer care (colorectal cancer) patients. They don’t need to do any traditional chemotherapy, radiation, or surgery. They will just observe for now.    DYNAMIC trial The second topic is…

ASCO 2022 Melanoma Overview: MOASC Spotlight   KEYNOTE-716 Study   Today, we talked about some of the exciting new discoveries that have been made with melanoma abstracts or clinical trial(s) over the course of the past year, at the ASCO 2022 annual meeting. The first thing that we did was look at the KEYNOTE-716 research presented at ASCO 2022 (melanoma), which was a comparison between using pembrolizumab as an adjuvant treatment and using a placebo. The stage 2 melanomas were the primary focus of the study.   And the recurrence-free survival rate for pts with stage 2B and stage 2C…

ASCO 2022 Breast Cancer Overview: MOASC Spotlight   DESTINY-Breast04 Data from ASCO 2022 Annual Meeting I presented a lot of data today because such exciting results came from 2022 ASCO annual meeting to this year. I first presented DESTINY-Breast04 studies, which showed. Significant improvement in progression-free survival and overall survival (OS) for HER2 positive breast cancer, in breast cancer research. Her2-Low metastatic breast cancer in a subset analysis or exploratory analysis in the hormone receptor (HR) negative, HER2-Low metastatic breast cancer patients. We did also see a benefit improvement in PFS and OS, even though it’s a small group of…

Olaparib Approved In Japan: Breast Cancer   Olaparib’s Study Design For BRCA1 or BRC2 Variants in Early Breast Cancer OlympiA was a global double-blind placebo-controlled randomized phase 3 trial that evaluated the efficacy and safety of one year of adjuvant Olaparib versus placebo in adult patients with germline pathogenic, BRCA1 or BRC2 breast cancer variants who had completed standard chemotherapy administered either as adjuvant or neoadjuvant therapy and had surgery and radiation therapy if needed for what needed to be a, at least a high risk early breast cancer or two negative stages of early breast cancer.   What About…

T-DXd HER2-Positive Breast Cancer: DESTINY-Breast03 DESTINY-Breast03 Phase 3 clinical trial Study Design for HER2-Positive Breast Cancer This was a safety update from the DESTINY-Breast03 Phase 3 clinical trial, and as everyone is aware, trastuzumab deruxtecan, which is a medicinal conjugate consisting of an antibody, was approved for patients with HER2-positive metastatic breast cancer. This medication was included in the earlier line setting because of the DESTINY-Breast01 and DESTINY-Breast03 studies. Patients in the second-line scenario who have previously been treated with trastuzumab and/or taxane in a metastatic disease setting or who have experienced a rapid relapse within six months of completing…

Calquence Tablet FDA Approved CLL, SLL, MCL Can You Tell Us The Significance Of The FDA’s Approval Of Calquence? The new Calquence tablet formulation provides an oral treatment option for physicians to consider for their patients in the US for chronic lymphocytic leukemia, small lymphocytic leukemia and patients with mantle cell lymphoma who have received at least one prior treatment option. Twenty to forty percent of patients with hematologic malignancies receive a gastric reducing agent, of which 70% of those are proton pump inhibitors (PPIs). Now, patients on a proton pump inhibitor can receive Calquence without having to change their…

NRG-GI008 (CIRCULATE-US) Colon Cancer Overview [2022] To watch Dr. Arvind Dasari discuss the NRG-GI008 presentation with slides, Click Here! NRG-GI008 (CIRCULATE-US) is really seeking to answer the question. Can circulating tumor DNA be used to guide therapy for lower risk stage III colon cancer? Now we know that circulating tumor DNA has really been a game changer in terms of how we learn more about not only the genomics of the cancers that we have but if there’s minimal residual disease still left in the body. But of course, part of the problem with knowing if there’s molecular presence of…

1992: Lung Cancer Action Project studies Chest CT Scan for Early Detection of Lung Cancer When we started the Early Lung Cancer Action Project (ELCAP) in 1992, chest CT (computed tomography) scanners were strong and powerful enough that they could acquire all the images of your lungs in a single breath hold. At that point, we decided that we could look at chest x-ray and a chest CT scan to determine how much earlier the chest CT scan allowed us to detect lung cancer in comparison to standard x-rays (lung cancer screening). Chest CT scanners first became available in the…

NRG-GI008 (CIRCULATE-US) Colon Cancer Overview [2022] To watch Dr. Arvind Dasari discuss the NRG-GI008 presentation with slides, Click Here! NRG-GI008 (CIRCULATE-US) is really seeking to answer the question. Can circulating tumor DNA be used to guide therapy for lower risk stage III colon cancer? Now we know that circulating tumor DNA has really been a game changer in terms of how we learn more about not only the genomics of the cancers that we have but if there’s minimal residual disease still left in the body. But of course, part of the problem with knowing if there’s molecular presence of…

Is Interstitial Lung Disease a Manageable Adverse Event of Trastuzumab T-DXd Deruxtecan Treatment? What is Trastuzumab T-DXd? Trastuzumab T-DXd is an antibody-drug conjugate that consists of an antibody that binds to the HER-2 receptor that can be over-expressed or mutated in several different cancers. That is covalently linked to a payload. In this case, it’s a topoisomerase one inhibitor, a very potent chemotherapeutic drug, which has high toxicity typically when administered systemically. So there are advantages to the antibody-drug conjugate approach so that the payload is delivered preferentially to cells that express the HER-2 receptor. When the antibody-drug conjugate binds…

Are you aware that Black men continue to suffer worse outcomes compared to White men with prostate cancer? Through this education, learners improve their ability to recognize systemic, behavioral and sociocultural factors creating disparate health outcomes in prostate cancer, improve identification of patients at risk, and expedite time to diagnosis and time to treatment.   Access the toolkit: https://www.prostatecancerdisparities.org/ Claim credit: https://www.achlcme.org/reduce-prostate-cancer-disparities-onctube

FRESCO-2 Trial Met Primary Endpoints in Patients With Metastatic Colorectal announced HUTCHMED from the Fruquintinib Global Phase III Trial The FRESCO-2 trial was a Phase 3 clinical trial that has been specifically created for patients that were previously treated with surgically unresectable metastatic colorectal cancer therapy. It was basically a 2:1 randomization for patients that had received prior standard chemotherapy and previously treated metastatic colorectal with Regorafenibor and Lonsurf. Patients may have been exposed to Regorafenib or Lonsurf or both of the drugs and the primary endpoint was overall survival. Just to keep things in perspective for patients, we tend…

In this panel discussion and workshop, experts from the University of Chicago Medicine and the University of Illinois Cancer Center discuss structural racism and disparities faced by women receiving breast cancer care. Discussion is centered around strategies to address these disparities. The experts are also joined by patient advocates sharing their personal experiences and how providers can provide support. This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of…

In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses the oncology, surgical, and radiation treatment experiences of white and Black women. Dr. Chen also reviews barriers, common misconceptions with breast cancer treatment, and interventions clinicians can employ to overcome racial disparities in breast cancer. This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of targeted interventions in improving breast cancer care for African American women…

In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses screening and mammography rates among racial/ethnic groups. Dr. Chen also touches on the impact of the COVID-19 pandemic, factors that influence disparities such as fears and misperceptions, the underutilization of genetic counseling and testing, and the importance of patient communication and navigation. Learn how you can address disparities in your own patient care. This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP,…